TON Web Exclusives

Although 5 years of neoadjuvant endocrine therapy improves disease-free survival in patients with early-stage breast cancer, the optimal duration of adjuvant therapy beyond 5 years has yet to be established. Results of a new study, suggesting that longer is not necessarily better, provide further insight on this topic.
An evaluation of more than 200 patients with breast cancer showed a near doubling of the risk for contralateral disease with dense breast tissue. This information may help clinicians counsel patients on their personal risk and options for treatment and surveillance.
Adding pertuzumab to standard therapy in women with HER2+ /HR+ locally advanced or metastatic breast cancer increased PFS, with no new safety signals identified.
No significant difference was found in survival between BRCA gene carriers and noncarriers among young patients with breast cancer. In addition, a consistent survival advantage was found in favor of BRCA carriers presenting with triple-negative breast cancer.
New data confirm the heterogeneity of HER2-positive breast cancer and may identify a subgroup of patients who benefit from dual HER2 blockade without the use of chemotherapy.
Page 6 of 6
Results 51 - 55 of 55